Later, this classification underwent several modifications, and it was widely accepted as a method to identify the prognostic significance of BC, in which the ER+ HER2− and luminal A tumors demonstrated a better prognosis, while the baseline and non-baseline triple-negative tumors had worse prognosis [38]. Here, ERBB2 is linked to breast cancer.